Example images from the (a) Cytoplasm dataset and (b) LIVECell dataset used for training and example images from each of our evaluation datasets, (c) PBL-HEK and (d) PBL-N2a. حسب Alexandra Dunnum VandeLoo (22209218)

الموضوعات:

The HMR C-terminus is required for HMR localization in proximity to centromeres and HP1a-bound chromatin. حسب Andrea Lukacs (3752956)

The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. حسب Andrea Lukacs (3752956)

HbA1c by BMI for new and previous diabetes diagnoses at start of TB treatment. حسب Sharon E. Cox (7243847)

الموضوعات:

Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcrip... حسب Mason A. McCool (11889842)

(a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automati... حسب Alexandra Dunnum VandeLoo (22209218)

الموضوعات:

First return maps of models for cases. حسب Nathan Thenon (13813389)

The rate the bias decreases with sample duration is higher for cells with higher activity levels. حسب Liron Sheintuch (12078310)

Comparison of estimated epidemic risks and reported increases in cases at the county level between March 16 and March 23, 2020. حسب Emily M. Javan (15194865)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Ribosomal subunit pathways are decreased in <i>Resf1</i> knockdown cells. حسب Megan R. Majocha (18529925)

"…<p>(A) GO Pathway analysis snapshots of various ribosomal subunit pathways that are decreased in 6DT1 <i>Resf1</i> KD cells. (B) The GO Cytosolic Ribosome pathway had many (C) small and large ribosomal proteins decreased in <i>Resf1</i> KD cells. …"

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)